As can be seen in Fig 6, a 4-day culture of CML CD34+ cells in the presence of FICZ was sufficient to significantly reduce their clonogenic potential in synergy with Imatinib (p = 0.039, Fig 6A) and Dasatinib (p = 0.0296, Fig 6B). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.